Remarkably, combination with anti-PD-1, and not anti-PD-L1, delays tumor appearance and growth (Fig. 6A), significantly increasing mice survival compared to treatment only with BLS (Fig. 6B). This evidence concerns the gene PDCD1 and neoplasm.